Diabetic Macular Edema Treated With Ozurdex (DMEO) — DMEO  

Diabetic Macular Edema Clinical Trial

Official title: Diabetic Macular Edema Treated With Ozurdex (DMEO)

Status Active, not recruiting

Clinical Trial Summary

to measure the pro-permeability factors VEGF, SDF-1, and angiopoietin-2 in the aqueous humor of patients with persistent/recurrent macular edema despite prior treatment with anti-VEGF agents

Clinical Trial Description

Patients with Diabetic Macular Edema (DME) are increasingly being treated with molecules targeting vascular endothelial factor (VEGF). One potential advantage of OZURDEX over specific VEGF antagonists is that steroids suppress production of multiple pro-permeability factors.

It is important to test the effect of OZURDEX in patients who have had a suboptimal response to VEGF antagonists to determine if OZURDEX provides more sustained benefit and to simultaneously assess its effect on aqueous levels of pro-permeability factors.

Our primary objective is to measure the pro-permeability factors VEGF, SDF-1, and angiopoietin-2 in the aqueous humor of patients with persistent/recurrent macular edema despite prior treatment with anti-VEGF agents at baseline and at 1, 2, 3, and 4 months after intraocular injection of OZURDEX. ;

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Diabetic Macular Edema
• Edema
• Macular Edema

• NCT number: NCT01951066
• Study type: Interventional
• Source: Johns Hopkins University
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: October 2013